Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Buprenorphine patches

Brand: 
NICE TA: 
Indication: Pain, in patients who are unable to take or tolerate oral medicine, (including soluble tablets and liquids).
Disease category: Central nervous system
Commissioning responsibility: CCG
PbR excluded: No

Background

Transdermal preparations lack the flexibility required when treating patients with fluctuating or uncontrolled pain. Use should be reserved for patients with stable pain who are unable to take or tolerate oral medicines. Buprenorphine patches are several times more expensive than equivalent doses of oral analgesics, and inappropriate use of transdermal preparations has cost implications for commissioners. It is recommended that the reason for using a patch is documented on initiation and if appropriate patients are switched to oral formulations at the earliest opportunity.

Recommendation

LMMG recommendation: Green (Restricted)
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for initiation in primary care, in line with restrictions (see background paragraph)

Supporting documents:

Position Statement : Use of Fentanyl & Buprenorphine Patches for Pain (Version 1.0)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Grey

Black